Who
Greg Pyszczymuka
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Aytu BioPharma; Director, Evoke Pharma.
In numbers
- Trades disclosed
- 29
- Buys
- 2
- Sells
- 0
- Bought
- $46K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 19 Dec 2022
- Last trade
- 28 Jul 2026
- Last filed
- 30 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Jul 2026filed 30 Jul 2026 | AYTU Aytu BioPharmaBiotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 28 Jul 2026filed 30 Jul 2026 | AYTU Aytu BioPharmaBiotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 17 Dec 2025filed 17 Dec 2025 | Evoke Pharmaoption or derivative | SEC FORM 4 Code D | —5,833 | filing |
| 17 Dec 2025filed 17 Dec 2025 | Evoke Pharmaoption or derivative | SEC FORM 4 Code D | —1,155 | filing |
| 3 Oct 2025filed 7 Oct 2025 | AYTU Aytu BioPharmaBiotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | Evoke Pharmaoption or derivative | SEC FORM 4 Code A | —1,155 at $0.00 | filing |
| 31 Mar 2025filed 31 Mar 2025 | AYTU Aytu BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —209 at $0.00 | filing |
| 31 Mar 2025filed 31 Mar 2025 | AYTU Aytu BioPharmaBiotechnology | SEC FORM 4 Code M | —209 | filing |
| 20 Feb 2025filed 24 Feb 2025 | Evoke Pharmaoption or derivative | SEC FORM 4 Code A | —5,833 at $0.00 | filing |
| 31 Dec 2024filed 2 Jan 2025 | AYTU Aytu BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —208 at $0.00 | filing |
| 31 Dec 2024filed 2 Jan 2025 | AYTU Aytu BioPharmaBiotechnology | SEC FORM 4 Code M | —208 | filing |
| 6 Nov 2024filed 8 Nov 2024 | AYTU Aytu BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 30 Sep 2024filed 2 Oct 2024 | AYTU Aytu BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —209 at $0.00 | filing |
| 30 Sep 2024filed 2 Oct 2024 | AYTU Aytu BioPharmaBiotechnology | SEC FORM 4 Code M | —209 | filing |
| 30 Jun 2024filed 2 Jul 2024 | AYTU Aytu BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —208 at $0.00 | filing |
| 30 Jun 2024filed 2 Jul 2024 | AYTU Aytu BioPharmaBiotechnology | SEC FORM 4 Code M | —208 | filing |
| 31 Mar 2024filed 2 Apr 2024 | AYTU Aytu BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —208 at $0.00 | filing |
| 31 Mar 2024filed 2 Apr 2024 | AYTU Aytu BioPharmaBiotechnology | SEC FORM 4 Code M | —208 | filing |
| 31 Dec 2023filed 2 Jan 2024 | AYTU Aytu BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —209 at $0.00 | filing |
| 31 Dec 2023filed 2 Jan 2024 | AYTU Aytu BioPharmaBiotechnology | SEC FORM 4 Code M | —209 | filing |
News
No headline names them, or the companies they trade most, lately.